Molecular analysis of immune checkpoint inhibitor associated erythema nodosum-like toxicity
The unique immune landscape at the EN-like irAE could indicate that this irAE is distinct from anti-tumor immune and analogous non-ICI autoimmune milieus. Our data also suggests that systemic immune activation induced by ICI treatment, as reflected in PBMC, may help monitor the patient's treatment response and access irAE risk.
Authors
- Yaomin Xu (ORCID: https://orcid.org/0000-0002-3752-4006)
- Xiaopeng Sun (ORCID: https://orcid.org/0009-0009-5219-8964)
- Jonathan L. Curry (ORCID: https://orcid.org/0000-0003-0630-6222)
- Douglas Buckner Johnson (ORCID: https://orcid.org/0000-0002-6390-773X)
- Paula I. González-Ericsson (ORCID: https://orcid.org/0000-0002-6292-6963)
- Violeta Sánchez (ORCID: https://orcid.org/0000-0001-6639-9024)
- Margaret L. Axelrod (ORCID: https://orcid.org/0000-0003-4713-8798)
- Elizabeth Jane Phillips (ORCID: https://orcid.org/0000-0002-7623-3383)
- Justin Micah Balko (ORCID: https://orcid.org/0000-0002-4263-5974)
- Yu Wang (ORCID: https://orcid.org/0000-0002-0635-1544)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Washington University in St. Louis (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-13
- DOI
- https://doi.org/10.3389/fimmu.2025.1542499
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05